NCT07505680

Brief Summary

The purpose of this pilot, single-arm clinical trial is to assess the effects of time-restricted feeding on overall health, including body composition, glycemic and lipidemic profile, as well as appetite-regulating hormones, including glucagon-like peptides 1(GLP-1) oxyntomodulin, glucagon. Additionally, the study aims to evaluate the impact of this dietary pattern on circadian rhythm parameters, including acrophase, mesor, and amplitude.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 4, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 16, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 15, 2026

Completed
3 months until next milestone

First Posted

Study publicly available on registry

April 1, 2026

Completed
Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

7 months

First QC Date

January 15, 2026

Last Update Submit

March 26, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes from baseline in appetite-regulating hormones , including GLP-1 in pg/mL, oxyntomodulin in pg/mL, and glucagon in pg/mL at week 4, measured by ELISA kits.

    Participants arrived at the laboratory between 08:30 and 09:00. An antecubital catheter was placed, and five blood samples were collected at fasting (0 min) and at 30, 60, 90, and 120 minutes after consuming the test meal. The test meal consisted of 100 g of S-Core FLEX Compact Protein powder (40 g carbohydrate, 29 g protein, 19 g fat) dissolved in 250 mL of water, providing 475 kcal.

    Baseline and Week 4

Secondary Outcomes (3)

  • Changes from baseline in circadian rhythm parameters (acrophase in degrees of Celcious, mesor in time units, amplitude in degrees of Celcious) at week 4, measured through continouous measurements in skin termperature by a thermistor.

    Baseline and Week 4

  • Changes from baseline in Body Composition, namely fat free mass in kg and fat mass in kg

    Baseline and week 4

  • Changes from Baseline in Glycemic and Lipidemic Profile, assessed by photometry.

    Baseline and Week 4

Study Arms (1)

Time-Restricted Feeding

OTHER

Participants followed a four-week regimen of ad libitum food intake from 08:00 to 18:00, followed by a 14-hour fasting period until 08:00 the next day, while maintaining habitual physical activity and sleep patterns.

Other: Time-Restricted Feeding

Interventions

Ad libitum food intake from 08:00 to 18:00, followed by fasting from 18:00 to 08:00 for four weeks. Outside the eating window, water and limited amounts (1-2 servings) of very low-calorie items (e.g., tea, diet soft drinks, coffee, chewing gum \<4 kcal/serving) were permitted. The intervention focused exclusively on the timing of food intake and did not impose restrictions on the quantity or type of foods consumed.

Time-Restricted Feeding

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men or women aged 18-35 years
  • Habitual daily eating window \>10 hours
  • Stable body weight over the past 3 months (\< ±10% change)
  • Able to provide informed consent independently

You may not qualify if:

  • Night shift work more than once per week
  • Presence of chronic diseases (e.g., cancer, renal or hepatic disease, inflammatory bowel disease, hypertension, diabetes, cognitive or psychiatric disorders)
  • Eating disorders
  • Use of medications affecting the intervention (e.g., corticosteroids, antidiabetics)
  • Pregnancy or planning pregnancy within the next 12 months
  • Diagnosis of insomnia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Harokopio University of Athens

Athens, Attica, 17676, Greece

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 15, 2026

First Posted

April 1, 2026

Study Start

June 4, 2025

Primary Completion

December 16, 2025

Study Completion

December 16, 2025

Last Updated

April 1, 2026

Record last verified: 2026-03

Locations